Condition

Colorectal Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 644 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials644

Recruiting133

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Researching the Effect of Exercise on CancerNCT04589468 · 2026-10-30

Evaluation of XYA02 in Patients With Advanced Solid TumorsNCT07670312 · 2026-09-17

Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fatigue 3 Months After Adjuvant Chemotherapy for CancerNCT07429487 · 2026-09-15

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial CancersNCT07545122 · 2026-09-01

SL-28 for Advanced Solid TumoursNCT07341737 · 2026-08-14

Precision Navigation to Improve Community Cancer Screening ParticipationNCT07676383 · 2026-08-04

TCR1188-ABC Cells in KRAS-mutated CancersNCT07594067 · 2026-08-01

A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid TumorsNCT07661641 · 2026-07-01

[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07702292 · 2026-06-30

Guaraná Supplementation for Cancer-Related FatigueNCT07816263 · 2026-06-20

Evaluation of Skin Tests in Biotherapy AllergiesNCT06971848 · 2026-06-17

Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line ImmunotherapyNCT07676461 · 2026-06-11

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid TumorsNCT07623369 · 2026-06-11

A Phase 1 Study of IM-1617 in Participants With Advanced CancerNCT07578571 · 2026-05-21

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced CancerNCT07225309 · 2026-05-01

18F-T2 PET/CT Imaging for CAIX Positive Solid TumorsNCT07557225 · 2026-04-27

Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support PersonsNCT07788729 · 2026-04-21

Remote Monitoring and Symptom Management Digital ApplicationNCT07553572 · 2026-04-14

CARE Tool Study Aim 3NCT07296887 · 2026-04-08

Optimizing Patient Treatment With EPA-enriched Nutrition, a Randomised Control TrialNCT07255066 · 2026-04-01

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant TumorsNCT07552467 · 2026-04-01

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid TumorsNCT07589205 · 2026-03-31

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsNCT07454642 · 2026-03-31

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors TypesNCT07503808 · 2026-02-24

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid TumorsNCT07189871 · 2026-02-23

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology IndicationsNCT07432633 · 2026-02-19

Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized TrialNCT07227077 · 2026-02-07

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid TumorsNCT07410676 · 2026-02-01

First in Human Study of SIM0610 in Solid TumorsNCT07348211 · 2026-01-19

Large Language Models Assist in Tumor MDTNCT07504367 · 2026-01-01

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid TumorsNCT07318805 · 2025-12-23

Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot TrialNCT07447050 · 2025-12-23

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic ProfilingNCT06717295 · 2025-12-20

The Florida ASCENT StudyNCT07042243 · 2025-12-05

FL-261 Imaging for Cancer Diagnosis and StagingNCT07510321 · 2025-11-27

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsNCT07261631 · 2025-11-24

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid TumorsNCT07300150 · 2025-11-21

Holistic Acupuncture for Patients With Chemotherapy Induced NauseaNCT07201194 · 2025-11-17

AI-Assisted Chemotherapy Side Effect ManagementNCT07198581 · 2025-11-12

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic CancerNCT07227168 · 2025-11-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid TumorsNCT07216105 · 2025-11-04

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsNCT07169734 · 2025-08-26

IDOV-Immune for Advanced Solid TumorsNCT06910657 · 2025-08-25

A Study of YL202 in Patients With Advanced Solid TumorsNCT07202364 · 2025-08-04

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsNCT07094204 · 2025-07-25

Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer SurvivorsNCT06371768 · 2025-07-14

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and SurvivalNCT06896162 · 2025-06-27

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsNCT07020221 · 2025-06-24

Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer PatientsNCT07673861 · 2025-05-23

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 ExpressionNCT06682793 · 2025-05-22

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)NCT06462963 · 2025-04-15

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)NCT07327489 · 2025-04-14

Impact of Aerobic Exercise on the Anticancer Immune Response in Patients Receiving Cancer TreatmentNCT06911970 · 2025-04-01

CT-95 in Advanced Cancers Associated With Mesothelin ExpressionNCT06756035 · 2025-03-31

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsNCT06695845 · 2025-01-14

Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid TumorsNCT06621563 · 2024-12-14

Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot TrialNCT06580002 · 2024-12-02

Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid TumorNCT07433283 · 2024-11-12

Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid TumorsNCT06819215 · 2024-10-30

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal CancersNCT06562192 · 2024-10-15

Common interventions

Leading sponsors

National Cancer Institute (NCI)13 M.D. Anderson Cancer Center10 Pfizer10 Memorial Sloan Kettering Cancer Center9 University Health Network, Toronto7 Eli Lilly and Company6 Genentech, Inc.6 Institut Bergonié6 AstraZeneca5 Duke University5 Fate Therapeutics5 Massachusetts General Hospital5 Merck Sharp & Dohme LLC5 Novartis Pharmaceuticals5 A2 Biotherapeutics Inc.4

Trial status mix

COMPLETED275

RECRUITING133

TERMINATED74

UNKNOWN68

ACTIVE_NOT_RECRUITING48

NOT_YET_RECRUITING25

WITHDRAWN13

ENROLLING_BY_INVITATION3

SUSPENDED3

APPROVED_FOR_MARKETING1

AVAILABLE1

Phase mix

PHASE1273

NA154

PHASE2145

PHASE315

EARLY_PHASE16

PHASE44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.